Data on patients suffering from Kawasaki disease have been collected prospectively in Finland since 1981. To ascertain the incidence, treatment and outcome in these patients the data were analysed for the 10-year period April 1982 to March 1992. Kawasaki disease was confirmed in 229 patients. The annual attack rate varied from 3.1 to 7.2 per 100,000 children below the age of 5 years. Their mean age was 3.9 years (range: 7 weeks to 39 years). 40% were under 2 years and 71% under 5 years of age. There was 1 adult patient. The male/female ratio was 1.5:1. Coronary artery lesions were found in 28 patients, 2 of whom died of myocardial infarction. Since April 1985, 132 patients (73%) have been treated with intravenous immunoglobulin. When treatment was begun before day 7 of the disease, coronary artery lesions were found in 5.5%; when begun between days 7 and 10, in 12%, and when begun after day 10, in 28% of the patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/00365549309008532 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk of Kawasaki Disease/Multisystem Inflammatory Syndrome Following COVID-19 Vaccination in Korean Children: A Self-Controlled Case Series Study.
J Korean Med Sci
January 2025
School of Pharmacy, Sungkyunkwan University, Suwon, Korea.
Background: Rare cases of Kawasaki disease (KD) and multisystem inflammatory syndrome in children (MIS-C) have been reported following the coronavirus disease 2019 (COVID-19) vaccination; however, the association between COVID-19 vaccination and the risk of developing KD/MIS-C has not yet been established.
Methods: We conducted a self-controlled case series analysis using a large-linked database that connects the COVID-19 immunization registry with nationwide claims data. We identified individuals aged < 18 years who received their initial COVID-19 vaccination and had a KD/MIS-C diagnosis with a prescription for intravenous immunoglobulin or corticosteroids between October 18, 2021, and April 15, 2023.
Association of respiratory infections with the incidence and treatment efficacy in Kawasaki disease.
Diagn Microbiol Infect Dis
January 2025
Department of Pediatrics, Nara Prefecture General Medical Center, Nara, Japan.
The etiology of Kawasaki disease (KD) has not yet been completely elucidated. We evaluated the temporal association between respiratory pathogens and KD incidence and the association between respiratory pathogens and treatment responsiveness in patients with KD. This retrospective study was conducted to compare the number of symptomatic children with pathogens detected using multiplex PCR tests with the number of KD cases.
View Article and Find Full Text PDFCoronary complications in Kawasaki disease: giant aneurysms and thrombosis leading to myocardial infarction.
Eur Heart J Imaging Methods Pract
January 2025
Eighth Floor Hospitalization, National Institute of Cardiology: Instituto Nacional de Cardiologia, Juan Badiano 1, Belisario Domínguez Secc 16, Tlalpan, Mexico City, Mexico 14080, Mexico.
Systemic artery aneurysms - A marker of high-risk Kawasaki disease.
Ann Pediatr Cardiol
December 2024
Department of Cardiovascular Radiology and Endovascular Interventions, All India Institute of Medical Sciences, Delhi, India.
Kawasaki disease, traditionally classified as medium vessel vasculitis, is known for the preferential involvement of coronary arteries. Infrequently, large systemic arteries might be involved and may affect the prognosis. Here, we present an infant with Kawasaki disease who had extensive involvement of large vessels such as the abdominal aorta and medium vessels of the extremities, along with giant coronary artery aneurysms.
View Article and Find Full Text PDFBiology-inspired dynamic microphysiological system approaches to revolutionize basic research, healthcare and animal welfare.
ALTEX
January 2025
F. Hoffmann-La Roche Ltd, Precision Safety, Product Development, Basel, Switzerland.
The regular workshops held by the Center for Alternatives to Animal Testing (CAAT) on biology-inspired microphysiological systems (MPS) taking place every four years, have become a reliable measure to assess fundamental scientific, industrial and regulatory trends for translational science in the MPS-field from a bird's eye view. The 2023 workshop participants at that time concluded that the technology as used within academia has matured significantly, underlined by the broad use of MPS and the steadily increasing number of high quality research publications - yet, broad industry adoption of MPS has been slow, despite strong interest. Academic research using MPS primarily aims to accurately recapitulate human biology in MPS-based organ models in areas where traditional models have been lacking key elements of human physiology, thereby enabling breakthrough discoveries for life sciences.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!